A multiple sclerosis patient shares essential guidance from her 13-year diagnostic journey, offering hope and practical tips ...

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

Think muscle twitches are harmless? Think again. Discover the hidden health risks and learn when to take action.

Denali Therapeutics Inc. (NASDAQ:DNLI) revealed topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS ...

Denali Therapeutics' DNL343 fails to slow ALS progression in phase 2/3 trial but shows safety and offers insights for future ...

Amyotrophic lateral sclerosis (ALS) is a rare neurological ... which is the area of the brain that controls the muscles in the neck and face. This article explores the symptoms of ALS that females ...

Muscle twitching is a significant cause for concern when accompanied by other neurological symptoms such as muscle weakness, ...

Denali Therapeutics said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial involving patients with amyotrophic lateral sclerosis (ALS), a fatal ...

The creatinine-to-cystatin C ratio may indicate the risk of developing amyotrophic lateral sclerosis, a large-scale database ...

Denali Therapeutics said the latest trial of its treatment for amyotrophic lateral sclerosis, or ALS, didn't meet its primary or secondary endpoints after 24 weeks.

Denali Therapeutics has reported that its Phase II/III HEALEY ALS Platform trial of DNL343 for ALS failed to meet its primary endpoint.